On June 24, ALNY gapped up by more than 30% after announcing that its drug Vutrisiran, used to treat transthyretin amyloid cardiomyopathy, delivered successful results. While the headline reason was fundamental, under the Adhishthana lens, this wasn't a random event. The stock was in Phase 9 at the time, a phase known for triggering supreme moves and powerful shifts in structure. Phase 9 is also where the stock typically breaks out of its Adhishthana Cakra and begins forming the Himalayan structure. That's ...

Alnylam Pharmaceuticals (ALNY) reported first-quarter 2025 adjusted loss of 1 cent per share, narrower than the Zacks Consensus Estimate of a loss of 56 cents. The company had incurred a loss of 16 cents per share in the year-ago quarter. The adjusted figure excluded items like stock-based compensation expenses and unrealized loss on marketable equity securities.Alnylam recorded total revenues of $594.2 million in the quarter, which surpassed the Zacks Consensus Estimate of $588.2 million. In the year-ago q ...